BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Simple Summary Apoptosis, a programmed form of cell death, represents the main
mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of …

Abstract Dual Bcl-2/Bcl-xL inhibitors are expected to deliver therapeutic benefit in many
haematological and solid malignancies, however, their use is limited by tolerability issues …

BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins
which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the …

Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …

Apoptosis is the major mode of programmed cell death, which conduces to maintain tissue
homeostasis, clearance of abnormal cells and development of organisms. Over the past two …

Background Pilocytic astrocytoma (PA) is the most common pediatric brain tumor and a
mitogen-activated protein kinase (MAPK)-driven disease. Oncogenic MAPK-signaling drives …

The PI3K pathway is commonly activated in breast cancer, with PI3K-AKT pathway inhibitors
used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K …

Simple Summary The development of BCL-2 inhibitors as a pivotal approach in cancer
treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a …

Purpose: Relapsed T-acute lymphoblastic leukemia (T-ALL) has limited treatment options.
We investigated mechanisms of resistance to BH3 mimetics in T-ALL to develop rational …